TORC1 inhibitor-focused resTORbio nets $90.9mm in IPO
Executive Summary
Just two months after closing a $40mm Series B round, resTORbio Inc. (therapies aimed at the mammalian target of rapamycin complex 1 (mTORC1) pathway) completed its initial public offering, netting $90.9mm through the sale of 6.5mm shares (including the overallotment) at $15, the mid-point of its anticipated range.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice